

Supplementary Table 5. Clinical and imaging findings associated with the progression-free survival: subgroup with FOLFOX

	Univariable analysis			Multivariable analysis		
	Hazard ratio	95% CI	P-value	Hazard ratio	95% CI	P-value
Age (year)	1.028	0.996–1.062	0.090	–	–	–
Male sex	0.943	0.510–1.746	0.853	–	–	–
Serum CEA level (ng/mL)	1.000	0.999–1.000	0.190	–	–	–
Change in SWV value (%)	1.023	1.008–1.038	0.003*	1.016	0.998–1.033	0.081
Non-responder (SD or PD)	2.737	1.451–5.164	0.002*	1.848	0.878–3.890	0.106
<i>KRAS</i> mutation	0.735	0.362–1.489	0.392	–	–	–
No. of CRLMs \geq 5	1.752	0.898–3.418	0.100	–	–	–
Primary rectal cancer	0.775	0.397–1.515	0.456	–	–	–
Resection of primary cancer	0.566	0.270–1.189	0.133	–	–	–
Metachronous CRLM	N/A			–	–	–
Presence of lymph node metastasis of primary cancer	1.382	0.581–3.289	0.464	–	–	–

FOLFOX, 5-fluorouracil, leucovorin, and oxaliplatin; CI, confidence interval; CEA, carcinoembryonic antigen; SWV, shear-wave velocity; SD, stable disease; PD, progressive disease; *KRAS*, Kirsten rat sarcoma virus; CRLM, colorectal liver metastasis; N/A, not available.

*P<0.05.

Supplementary Table 6. Clinical and imaging findings associated with the progression-free survival: subgroup with FOLFIRI

	Univariable analysis			Multivariable analysis		
	Hazard ratio	95% CI	P-value	Hazard ratio	95% CI	P-value
Age (year)	1.050	0.972–1.135	0.213	–	–	–
Male sex	0.718	0.226–2.286	0.575	–	–	–
Serum CEA level (ng/mL)	1.000	0.999–1.001	0.495	–	–	–
Change in SWV value (%)	1.033	0.994–1.074	0.099	–	–	–
Non-responder (SD or PD)	7.808	1.416–43.06	0.018*	–	–	–
<i>KRAS</i> mutation	0.410	0.123–1.363	0.146	–	–	–
No. of CRLMs \geq 5	3.039	0.887–10.41	0.077	–	–	–
Primary rectal cancer	2.552	0.491–13.27	0.266	–	–	–
Resection of primary cancer	0.317	0.058–1.753	0.188	–	–	–
Metachronous CRLM	0.738	0.222–2.460	0.621	–	–	–
Presence of lymph node metastasis of primary cancer	0.288	0.058–1.430	0.128	–	–	–

FOLFIRI, 5-fluorouracil, leucovorin, and irinotecan; CI, confidence interval; CEA, carcinoembryonic antigen; SWV, shear-wave velocity; SD, stable disease; PD, progressive disease; *KRAS*, Kirsten rat sarcoma virus; CRLM, colorectal liver metastasis.

*P<0.05.